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Abstract
Objective—To evaluate the relationship of maternal antenatal magnesium sulfate (MgSO4) with 
neonatal cranial ultrasound abnormalities and cerebral palsy (CP).
Study design—In a randomized trial of MgSO4 or placebo in women at high risk of preterm 
delivery, up to three cranial ultrasound were obtained in the neonatal period. Images were 
reviewed by at least two pediatric radiologists masked to treatment and other clinical conditions. 
Diagnoses were predefined for intraventricular hemorrhage (IVH), periventricular leukomalacia 
(PVL), intracerebral echolucency or echodensity, and ventriculomegaly. CP was diagnosed at two 
years by standardized neurological examination.
Results—Intraventricular hemorrhage, PVL, intracerebral echolucency or echodensity, and 
ventriculomegaly were all strongly associated with an increased risk of CP. MgSO4 administration 
did not affect the risk of cranial ultrasound abnormality observed at 35 weeks post-menstrual age 
or later. However, for the 82% of infants born at <32 weeks gestation, MgSO4 was associated with 
a reduction in risk of echolucency or echodensity. The reduction in risk for echolucency explained 
21% of the effect of MgSO4 on CP (p=0.04), and for echodensity explained 20% of the effect 
(p=0.02).
Conclusions—MgSO4 given prior to preterm delivery was associated with decreased risk of 
developing echodensities and echolucencies at <32 weeks gestation. However, this effect can only 
partially explain the effect of MgSO4 on CP at two years of age.
Keywords
cranial ultrasound; magnesium sulfate; echodensity; echolucency; intraventricular hemorrhage; 
periventricular leukomalacia; germinal matrix
Infants born before 32 weeks of gestation account for almost 2% of all births in the United 
States (1). These infants are at the highest risk for poor neurodevelopmental outcomes, most 
frequently poor intellectual outcome and cerebral palsy (CP) (2–9).
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In prematurely born infants, cerebral lesions detected by neuroimaging are strongly 
associated with adverse neurodevelopmental outcome (10). Cystic periventricular white 
matter injury, ventricular dilatation, and germinal matrix hemorrhage can readily be detected 
by cranial ultrasound, although noncystic white matter injury is not as well visualized. 
Because cystic manifestations of injuries may take 2–5 weeks to develop, it is important to 
repeat ultrasound scans over time (11). In infants whose findings are not cystic and resolve 
in the neonatal period, prognosis is improved over those who develop cystic lesions (12). 
Not all children who develop CP have identifiable neonatal cranial ultrasound lesions. In 
one study, 6% of infants with no lesions born at gestational age 28–32 weeks and 8% at 
gestational age < 28 weeks developed CP (13); in another study, 4% of those with no lesions 
born at gestational age < 30 weeks had CP (14), and in a third study of infants <1000 grams 
at birth, CP occurred in 9.4% (15) of those with no lesions. In contrast, 28 to 52% of those 
who do have cranial ultrasound lesions will develop CP (10, 14).
A meta-analysis of several trials has shown that magnesium sulfate (MgSO4) administered 
to women at risk of delivering before 32 weeks of gestation reduces CP in their infants (16). 
As part of a randomized trial to test whether antenatal MgSO4 administered to women about 
to deliver prematurely reduces the risk of CP in their children, serial neonatal cranial 
ultrasounds were obtained on the infants (17). Because it is not known whether MgSO4 has 
an effect on the cerebral lesions detected during the neonatal period or whether the reduction 
of the risk of CP is through some other pathway, in this secondary outcome study we sought 
to evaluate whether there is a protective effect of MgSO4 on cranial ultrasound 
abnormalities that may mediate the decrease seen in CP at age two years.
Methods
The primary trial was conducted by the Maternal Fetal Medicine Units Network of the 
Eunice Kennedy Shriver National Institute of Child Health and Human Development 
(ClinicalTrials.gov: NCT00014989). A total of 2241 women between 24 and 32 weeks 
gestation were randomized to receive either MgSO4 (loading dose 6 gm infused over 20–30 
minutes followed by maintenance infusion of 2 gm/hr) or an identical appearing placebo. 
Eligible women were at high risk of preterm delivery due to ruptured membranes or 
advanced preterm labor, or fetal indication for delivery (eg, severe growth restriction). 
Neurodevelopmental outcome was evaluated at 6 months, 12 months, and 24 months, 
corrected for prematurity. CP was diagnosed at 24 months by examiners masked to study 
treatment assignment (17). Examiners attended central training sessions and were annually 
certified through videotaped exams. The study was approved by the institutional review 
boards of all participating clinical centers, and all enrolled women gave written informed 
consent. Details of the protocol are available elsewhere (17).
All infants received up to three cranial ultrasound per study protocol. Those born at term had 
a head ultrasound during the delivery admission or within a week of discharge, and those 
born at 32 weeks 0 days to 36 weeks 6 days had a head ultrasound at 35 – 40 weeks post-
menstrual age. Those born before 32 weeks of gestation could have up to three ultrasounds: 
the first before 3 days of age, the second at 3 to 4 weeks of age and a third at 35 weeks post-
menstrual age or at discharge, whichever was later. At least three coronal and three sagittal 
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views were obtained for each study via the anterior fontanelle. For the purposes of this 
report the cranial ultrasound that was conducted at 35 weeks or later for each infant is 
designated as the “term” ultrasound.
Images were reviewed centrally by a team of three pediatric radiologists very experienced in 
cranial ultrasound interpretation. Each image was reviewed independently by two of the 
three. When there was disagreement, the third radiologist adjudicated the reading and a 
consensus diagnosis was determined (among the three radiologists). Prior to each reading 
session, a set of 10 reference cases with various abnormalities were reviewed to reinforce 
the agreed-upon scoring criteria. The radiologists were masked to any clinical findings 
including study treatment assignment.
Studies were evaluated for the presence of germinal matrix hemorrhage, periventricular 
leukomalacia (echodense and/or echolucent), intracerebral echolucency or echodensity, and 
ventriculomegaly. The Papile and Burnstein scoring system was used for germinal matrix 
hemorrhage (18). For this study, grade III was diagnosed when the amount of blood was 
sufficient to fill and distend the ventricles, i.e., a small intraventricular hemorrhage (IVH) 
within an enlarged ventricle due to post hemorrhagic hydrocephalus and not due to further 
distension by subsequent hemorrhage was not upgraded to grade III. However, if more 
bleeding occurred and the additional blood distended the ventricles, the IVH was upgraded 
to grade III. All parenchymal abnormal lesions were categorized as echogenic or echolucent. 
These were further categorized as grade IV periventricular hemorrhagic infarcts or 
periventricular leukomalacia (PVL) when appropriate. Ventriculomegaly was defined as 
temporal and lateral horn dilatation, with or without cortical thinning.
Analyses were conducted on two cohorts of infants: the whole cohort comprising data from 
the term ultrasound, and the cohort of those born at less than 32 weeks of gestation using 
data from all the ultrasounds (up to three). For the babies born at less than 32 weeks of 
gestation, a finding was considered present if diagnosed at any of the ultrasounds.
Statistical Analyses
For each analysis cohort, the effect of MgSO4 versus placebo on each cranial ultrasound 
abnormality was analyzed by log binomial regression, taking into account the correlation 
between twins. The association of each cranial ultrasound abnormality with CP was also 
analyzed, with similar methods. Lastly, mediation analysis was used to examine the 
relationship of both MgSO4 and cranial ultrasound abnormalities with CP. In order to 
compute the mediation effect, first the main effect of MgSO4 on CP was estimated. Second, 
a separate model with each cranial ultrasound abnormality added was constructed, and the 
change to the main effect of MgSO4 was computed. The Sobel test was used to assess if the 
amount of mediation was different from zero (19). To assess the potential effect of missing 
CP outcomes due to death after neonatal discharge (a competing risk), analyses were 
repeated with a combined outcome of CP or death. A nominal p-value of <0.05 was chosen 
to denote significance. No adjustments were made for multiple comparisons.
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Enrollment lasted from December 1997 to May 2004. Of the 2241 women (2444 fetuses) 
who were included in the trial, 2110 infants were discharged alive and had at least one 
cranial ultrasound (Figure; available at www.jpeds.com). An assessment for CP was 
performed on 1979 of the children (94%) at two years of age. Table I shows the 
characteristics of the children in the cohort: 953 of the children (48%) were in the MgSO4 
group, and 1026 in the placebo group; 1613 (82%) were born before 32 weeks of gestation 
and 17% were twins. In the 1979 children in this analysis, as in the overall trial, MgSO4 was 
associated with a reduction in CP in the children at two years of age: 4.2% in the MgSO4 
group versus 6.9% in the placebo group (OR 0.59; 95% CI 0.39–0.88). MgSO4 was also 
associated with a reduced risk of CP (OR 0.63, 95% CI 0.42–0.95) among the 1613 infants 
born before 32 weeks.
An initial discrepancy between the two radiologists assigned to read each ultrasound was 
found in 14% of the films. This included both disagreement on the presence or absence of 
any ultrasound finding, and a difference in degree (eg, a discrepancy between the reviewers 
of IVH grade III versus IV). Ninety percent (n=1776) had the term ultrasound. The 
remaining 10% did not differ by rate of MgSO4 assignment, but were born at a later 
gestational age and had a shorter hospital stay than those who did have the term ultrasound.
There was no effect of MgSO4 on any of the cranial abnormalities detected on the term 
ultrasound (Table II). Echolucency, PVL, ventriculomegaly, and IVH observed in the term 
ultrasound were all strongly associated with CP (all p < 0.001), with odds ratios varying 
from 3.1 (any IVH) to 70.9 (PVL) (Table III). However, there was no mediation effect of 
term-ultrasound cranial ultrasound abnormalities on CP (all p>0.05).
In the group of infants born before 32 weeks and receiving serial ultrasounds, there was a 
reduced risk of echodensity (OR 0.38, 95% CI 0.19–0.79) and echolucency (OR 0.59, 95% 
CI 0.36–0.97) detected on any ultrasound for those receiving MgSO4 (n=777) compared 
with placebo (n=836; Table II). All reported cranial abnormalities were strongly associated 
with CP (all p < 0.001), with odds ratios varying from 3.3 (any IVH) to 34.9 (PVL) (Table 
IV). Twenty-nine percent (24/84) with ventriculomegaly on any scan developed CP, 43% 
(18/42) with grade III/IV IVH, and 67% (22/33) with PVL. The decrease in echodensity and 
echolucency associated with MgSO4 partially explains the reduction in CP due to MgSO4. 
When the presence of echodensity was added to the regression model examining the effect 
of MgSO4 on CP, the OR of CP increased from 0.63 to 0.69. Reduction of echodensity 
explains 20% of the effect of MgSO4 on reducing CP (p=0.02). Very similar mediation 
effects are seen for echolucencies. The effect of MgSO4 on reducing echolucencies explains 
21% of the effect of MgSO4 on CP (p=0.04). There were no mediation effects seen with 
PVL (3%), ventriculomegaly (1%) or IVH (3%). However, 11% (p=0.10) of the effect of 
MgSO4 on CP is explained by the reduction of IVH grade III or IV.
In order to measure any potential effect of missing CP diagnoses for those who died after 
initial neonatal hospital discharge but before the child’s neurodevelopmental exam (MgSO4: 
6 deaths following and 12 not following cranial ultrasound abnormality; Placebo: 3 deaths 
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following and 14 not following cranial ultrasound abnormality), all analyses with CP were 
repeated with a combined outcome of CP or death. None of the findings were substantially 
changed from those with CP alone (Tables V and VI; available at www.jpeds.com).
Discussion
Our data reaffirm the previously documented strong association of neonatal cranial 
ultrasound findings (ventricular dilatation, PVL, and IVH) with CP (20–23). Prenatal 
MgSO4 in prospective and retrospective studies has also been associated with a decreased 
risk of IVH and white matter disease in infants born preterm (24–27). Other studies did not 
find a decrease in IVH with MgSO4 (28,29). In the French PREMAG study, which had a 
higher rate of maternal-fetal infection and only enrolled 62% of the planned sample size, 
there were non-significant decreases seen in white matter disease in the group treated with 
MgSO4 compared with placebo (30).
Randomized controlled trials and observational studies have found a decreased risk of CP 
when MgSO4 is administered to women with threatened preterm delivery (16,22,23). 
Previously, we determined in our primary trial that MgSO4 administration was associated 
with a reduced rate of CP among survivors to age 2 years (17). In this study we explored 
whether the decreased risk of CP following MgSO4 administered before delivery was 
mediated by the relationship of treatment to abnormalities seen on early cranial ultrasound 
examinations. We did find a decrease in clinically important cranial ultrasound lesions in 
those who had been treated with MgSO4 compared with placebo. Although the effect on 
echolucencies and echodensities was statistically significant for our early preterm group, the 
point estimates of the odds ratios for echolucency were very similar in our early preterm 
group (OR 0.59, p=0.04) and for the term ultrasound in the entire population (OR 0.60, 
p=0.06). Furthermore, we found that this reduction of cranial ultrasound abnormalities 
partially explained the reduction of CP from MgSO4.
There are a number of possible mechanisms by which MgSO4 could mediate its protective 
effect, including blocking the N-methyl-D-aspartate receptors that allow glutamate release 
and influx of calcium (16), increasing platelet aggregation and adhesion, enhancing immune 
response and modulating inflammatory reactions, and stabilizing membranes with reduction 
in free radicals (31). MgSO4 can reduce the risk of cell death by decreasing proinflammatory 
cytokines or free radicals produced during hypoxic-ischemic reperfusion (32). The 
compound may also have a beneficial effect by lowering neonatal cerebral blood flow (33), 
especially in IVH, when fluctuations of cerebral blood flow and fragility of the germinal 
matrix cerebrovasculature may have a role in causing damage (34).
There are several limitations of our study. Although the most recent American Academy of 
Neurology practice guideline on neonatal neuroimaging recommends cranial ultrasound 
serially in preterm neonates <30 weeks of gestation (35), MRI and advanced MRI 
techniques provide a more detailed assessment, particularly at term and later (36). Our study 
did not have MRI imaging and thus lesions such as focal noncystic white matter 
abnormalities may have been missed. However, by performing serial cranial ultrasound in 
the neonatal period, including term gestational age, most severe abnormal white matter 
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injury can be detected by the development of cystic leukomalacia; moderate and mild injury 
is less reliably detected. Echodensities in the periventricular white matter, which may be 
ipsilateral to a hemorrhage (ie, Grade IV IVH) or may occur independently of IVH, often 
bilaterally (ie, PVL), may gradually change to echolucencies and end up as visible cystic 
lesions (37). Furthermore, although it would have been informative to perform an analysis of 
those diagnosed with moderate to severe CP (without mild CP), the relatively low rates in 
our cohort precluded this more limited analysis.
Although the proportions of study infants without any cranial ultrasound (6.9%) or without a 
two-year exam for CP (4.6%) were relatively small, it is possible that these missing data 
could have an impact on our results. Not surprisingly, those without the term scan were 
more likely to have been born at a later gestational age and to have a shorter postnatal 
hospital stay. These neonates in general would be less likely to have demonstrated cranial 
ultrasound abnormalities or have CP. Interestingly, those who did have a cranial ultrasound 
but subsequently lost to follow-up before the two-year exam (n=95) were more likely to 
have PVL identified on the term scan (but not any other cranial ultrasound abnormality). 
However, there was no imbalance by treatment group, either in general between those lost to 
follow-up and not, or specifically in those with PVL.
This study provides an in-depth analysis of the cranial ultrasound findings not previously 
described from a large clinical trial of neonates. In summary, about one quarter of the infants 
examined with cranial ultrasound had one or more of the following sonographic 
abnormalities: parenchymal echodensities, parenchymal echolucencies, ventriculomegaly, 
IVH, or any combination. We confirmed that abnormalities identified by cranial ultrasound 
were strongly associated with CP. We saw no effect of MgSO4 on cranial ultrasound 
findings done at a late post-conceptual age (equivalent to >35 weeks) for the entire cohort, 
but for those born <32 weeks gestation, MgSO4 was associated with a lowered risk of 
specific cranial ultrasound abnormalities, thus providing a possible mechanism by which 
MgSO4 exerts its protective effect on CP. There was a reduced risk of echodensity or 
echolucency in those given MgSO4 compared with placebo, and we observed a mediation of 
the effect on CP attributable to those same abnormalities. This new information from our 
study adds to the prognostic information available to neonatologists when counseling 
families, particularly with the increased use of antenatal MgSO4 for CP prevention.
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Table 1
Patient Characteristics
MgSO4 (n=953) Placebo (n=1026)
Number of cranial ultrasounds, n (%)
 One 257 (27.0%) 263 (25.6%)
 More than one 696 (73.0%) 763 (74.4%)
Cranial ultrasound at 35 weeks or greater, n (%) 854 (89.6%) 922 (89.9%)
Gestational age at birth, n (%)
 < 32 weeks 777 (81.5%) 836 (81.5%)
 32 weeks or greater 176 (18.5%) 190 (18.5%)
Birth weight, g, mean (SD) 1417 (537) 1428 (556)
Twins, n (%) 151 (15.8%) 188 (18.3%)
Male, n (%) 508 (53.3%) 519 (50.6%)
Female, n (%) 445 (46.7%) 507 (49.4%)
Maternal self-reported race, n (%)
 African American 431 (45.2%) 442 (43.1%)
 Caucasian 343 (36.0%) 376 (36.7%)
 Hispanic 157 (16.5%) 185 (18.0%)
 Other 22 (2.3%) 23 (2.2%)
Maternal education, yr, median (interquartile range) 12 (11 – 13) 12 (11 – 13)
Antenatal steroids, n (%) 924 (97.0%) 998 (97.3%)
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